Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 108 | 71 | 0 |
| Samples | 77 | 64 | 0 |
| Peptides | 103 | 66 | 0 |
Function
FCSK · Fucose kinase
The protein encoded by this gene belongs to the GHMP (galacto-, homoserine, mevalonate and phosphomevalonate) kinase family and catalyzes the phosphorylation of L-fucose to form beta-L-fucose 1-phosphate. This enzyme catalyzes the first step in the utilization of free L-fucose in glycoprotein and glycolipid synthesis. L-fucose may be important in mediating a number of cell-cell interactions such as blood group antigen recognition, inflammation, and metastatis. While several transcript variants may exist for this gene, the full-length nature of only one has been described to date. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 101 amino-acid changes on canonical ENST00000288078 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in FCSK · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in FCSK – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 5/40 12% | 0/0 0% |
| Glioblastoma | 2/98 2% | 0/0 0% |
| Acute Myeloid Leukemia | 1/90 1% | 0/0 0% |
| Mesothelioma | 2/62 3% | 0/165 0% |
| Hodgkins Lymphoma | 1/16 6% | 0/122 0% |
| Endometrial Carcinoma | 3/42 7% | 1/612 0% |
| Ovarian Carcinoma | 4/109 4% | 1/998 0% |
| Melanoma | 7/210 3% | 2/1899 0% |
| Non-Small Cell Lung Carcinoma | 5/304 2% | 1/1390 0% |
| Colorectal Carcinoma | 9/143 6% | 1/3239 0% |
| Neuroblastoma | 4/87 5% | 0/1331 0% |
| Other Sarcomas | 2/69 3% | 0/699 0% |
| Squamous Cell Lung Carcinoma | 2/57 4% | 0/810 0% |
| Cervical Carcinoma | 0/35 0% | 1/422 0% |
| Biliary Tract Carcinoma | 2/54 4% | 0/950 0% |
| Neuroendocrine Tumour | 1/154 1% | 0/577 0% |
| Glioma | 2/52 4% | 1/2127 0% |
| Head and Neck Carcinoma | 1/85 1% | 1/1574 0% |
| Bladder Carcinoma | 0/58 0% | 1/956 0% |
| Hepatocellular Carcinoma | 1/46 2% | 1/2210 0% |
| Prostate Carcinoma | 2/13 15% | 0/2105 0% |
| B-Lymphoblastic Leukemia | 2/55 4% | 0/2640 0% |
| Thyroid Gland Carcinoma | 1/45 2% | 0/1592 0% |
| Breast Carcinoma | 1/144 1% | 1/3264 0% |
| Pancreatic Carcinoma | 0/89 0% | 1/1611 0% |
| Gastric Carcinoma | 1/74 1% | 0/1809 0% |
| Kidney Carcinoma | 1/85 1% | 0/1862 0% |
| Other Blood Cancers | 1/61 2% | 0/2725 0% |
| B-Cell Non-Hodgkins Lymphoma | 1/88 1% | 0/2534 0% |
Mutation Distribution
Where FCSK is mutated · all tissues, split by cell line vs tissue
How many mutations in FCSK were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
Mutations
All 108 mutations in FCSK
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|